Texas Vioxx ruling stands

Share this article:
The Texas judge who reduced the $32 million awarded to a plaintiff in a Vioxx case yesterday has also rejected Merck's request to reverse the jury's decision that Vioxx caused the plaintiff's heart attack, The Wall Street Journal reported.

In April, a Rio Grande City, Texas, jury awarded Felicia Garza and her sons $32 million after finding Merck liable for the death of Leonel Garza.

In the months following the verdict, a woman not connected to the trial came forward and said that she had witnessed Mrs. Garza exchanging money with juror Jose Manuel Rios. In depositions, Rios said that he had borrowed thousands of dollars from Mrs. Garza over the years, but didn't have any outstanding debts at the time of the trial. Merck conducted post-trial discovery in the matter and after reviewing bank and phone records found there were more than a dozen calls between Rios's phone and Mrs. Garza during the case.

Travis Sales, a Merck defense attorney said, “Obviously, we had hoped the judge would enter a judgment in Merck's favor.” Sales said Merck will file a motion for a new trial within 30 days, based on the undisclosed relationship between plaintiff and juror.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...